Improvement in long-term survival with mesenchymal stem cell transplantation in systemic sclerosis patients: a propensity score-matched cohort study

作者：Wenyi Yuan, Mian Liu, Dapeng Yang, Yirui Shi, Zhikang Wang, Xuan Cao, Jun Liang, Linyu Geng, Huayong Zhang, Xuebing Feng, Ziyi Jin, Dandan Wang, Lingyun Sun · 发表于：Stem Cell Research & Therapy · 年份：2025 · DOI：10.1186/s13287-025-04237-1 · 被引用次数：9 · 研究领域：Systemic Sclerosis and Related Diseases、Mesenchymal stem cell research、Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

BACKGROUND: The intricate and varied clinical presentations of systemic sclerosis (SSc) pose significant challenges for treatment. While several studies have investigated the therapeutic potential of mesenchymal stem cell transplantation (MSCT), the clarity of its long-term outcomes for SSc patients is still lacking. METHODS: Data on MSCT were extracted from the medical records of inpatients at Nanjing Drum Tower Hospital between January 2013 and December 2022. Additionally, Baseline characteristics and survival outcomes were ascertained from medical records and telephone follow-up. Propensity score matching (PSM) was employed to equalize the baseline characteristics of the patient groups, while survival analysis and multivariate Cox regression assessed the relationship between received MSCT and all-cause mortality and disease-specific survival rates in SSc patients. RESULTS: Of the 333 hospitalized SSc patients, 113 patients underwent MSCT. The log-rank test revealed significantly higher survival rates in the MSCT group compared to the control group (10-year survival rate 89.4% vs. 73.4%, P = 0.002). In the PSM cohort, receiving MSCT significantly reduced mortality (10-year survival 88.0% vs. 79.9%, P = 0.032). Multivariate Cox regression analysis indicated that MSCT was linked to a reduced mortality risk during the follow-up period (HR 0.38, 95% CI 0.19-0.75, P = 0.005). This finding was further confirmed in the matched cohort (HR 0.38, 95% CI 0.18-0.82, P = 0.014). Subgrou...